XXXVIII
Congreso de la Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica
57
31.
Edlmayr J, Niespodziana K, Linhart
B, Focke-Tejkl M, Westritschnig K,
Scheiblhofer S, et al. A combination
vaccine for allergy and rhinovirus
infections based on rhinovirus-de-
rived surface protein VP1 and a
nonallergenic peptide of the major
timothy grass pollen allergen Phl p
1. J Immunol 2009; 182:6298- 306;
32.
Klimek L,Willers J, Hammann-Haen-
ni A, et al. Assessment of clinical ef-
ficacy of CYT003-QbG10 in patients
with allergic rhinoconjunctivitis: a
Phase IIb Study. Clin Exp Allergy
2011; 41:1305–1312
33.
Smits HH, Engering A, van der Kleij
D, et al. Selective probiotic bacte-
ria induce IL-10-producing regula-
tory T cells in vitro by modulating
dendritic cell function through
dendritic cell-specific intercellular
adhesion molecule 3-grabbing no-
nintegrin. J Allergy Clin Immunol
2005; 115:1260 – 1267.
34.
Moussu H, Van Overtvelt L, Horiot S,
Tourdot S, Airouche S, Zuercher A,
Holvoet S, Prioult G, Nutten S, Mer-
cenier A, mascarell L, Moingeon P.
Bifidobacterium bifidum NCC453
promotes tolerance induction in
murine models of sublingual imm-
nunotherapy. Int Arch Immnunol
2012;158(1):35-42
35.
Pizza M, Giuliani MM, Fontana MR,
Monaci E, Douce G, Dougan G, et al.
Mucosal vaccines: non toxic deriva-
tives of LT and CT as mucosal adju-
vants. Vaccine 2001; 19:2534-41;
36.
Pfaar O, Barth C, Jaschke C, et al.
Sublingual allergen-specific immu-
nother-apy adjuvanted with mono-
phosphoryl lipid A: a phase I/IIa stu-
dy. Int Arch Allergy Immunol 2011;
154:336–344.
37.
Van Overtvelt L, Lombardi V, Raza-
findratsita A, Saint-Lu N, Horiot S,
Moussu H, et al. IL-10-inducing ad-
deviation in favour of Th1 respons-
es. Allergy 2005; 60:678–684.
24.
Martin M, Michalek SM, Katz J.
Role of innate immune factors in
the adjuvant activity of monophos-
phoryl lipid A. Infect Immun 2003;
71:2498–2507.
25.
Drachenberg KJ, Wheeler AW, Stue-
bner P, Horak F. A well tolerated
grass pollen-specific allergy vac-
cine containing a novel adjuvant,
monophosphoryl lipid A, reduces
allergic symptoms after only four
preseasonal injections. Allergy
2001; 56:498–505.
26.
Dubuske L, Frew A, Horak F, et al.
Ultrashort-specific immunothera-
py successfully treats seasonal al-
lergic rhinoconjunctivitis to grass
pollen. Allergy Asthma Proc 2011;
32:239–247.
27.
Ku¨ ndigTM, Senti G, Schnetzler G,
et al. Der p 1 peptide on virus-like
particles is safe and highly immu-
nogenic in healthy adults. J Aller-
gy Clin Immunol 2006; 117:1470–
1476.
28.
SentiG, Johansen P, Haug S, et al.
Use of A-type CpG oligodeoxynu-
cleotides as an adjuvant in aller-
gen-specific immunotherapy in hu-
mans: a phase I/IIa clinical trial. Clin
Exp Allergy 2009; 39:562–570.
29.
Schmitz N, Dietmeier K, Bauer M,
Maudrich M, Utzinger S, Muntwi-
ler S, et al. Displaying Fel d1 on
virus-like particles prevents reacto-
genicity despite greatly enhanced
immunogenicity: a novel therapy
for cat allergy. J Exp Med 2009;
206:1941- 55;
30.
Crameri R, Kündig TM, Akdis CA.
Modular antigentranslocation as
a novel vaccine strategy for aller-
genspecific immunotherapy. Curr
Opin Allergy Clin Immunol 2009;
9:568-73;
